CellWell record HH-0025
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
Wise RA, Holbrook JT, Criner G, Sethi S, Rayapudi S, Sudini KR, Sugar EA, Burke A, Thimmulappa R, Singh A, Talalay P, Fahey JW, Berenson CS, Jacobs MR, Biswal S.
PLOS ONE ยท 2016
In plain language
A randomized, placebo-controlled human trial of the Nrf2 activator sulforaphane found no significant increase in Nrf2-regulated gene expression in COPD patients, an honest null result that illustrates the gap between Nrf2 activation in cell models and confirmed effects in humans.
- Design
- Randomized controlled trial
- Studied in
- Human
Cite this record: https://thecellwell.org/studies/HH-0025
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.